To contentTo navigationTo search
Logotype

Welcome to Implantica

Select your region of residence below to learn more about Implantica and RefluxStop™, our innovative solution for GERD.

We are working on making RefluxStop™ available globally.

Europe

RefluxStop™ is CE marked in Europe. It is currently available in:

  • Austria
  • France 
  • Italy
  • Germany
  • Norway
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Europe

USA & Other

RefluxStop® is not available for sale in all other countries including the USA.


For additional information contact our customer support:

customer.support@implantica.com

USA & Other

You are about to navigate to a different regional section of the website.

Please confirm your country of residence below.

Europe

RefluxStop™ is CE marked in Europe. It is currently available in:

  • Austria
  • France 
  • Italy
  • Germany
  • Norway
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Europe

USA & Other

RefluxStop® is not available for sale in all other countries including the USA.


For additional information contact our customer support:

customer.support@implantica.com

USA & Other


Bringing advanced
technology into the body


Advanced technology has completely changed our daily lives. Implantica has spent over a decade developing and patenting how to bring such advances into the body.

Our Mission

Cornerstone Platform Technologies

Implantica has spent over a decade developing and patenting how to bring technological advances into the body. These technologies are still in development and not yet commercially available.

Learn more

Smart Medical Implants Pipeline

Medical implants previously seen as unachievable will seek to alleviate unmet medical needs (products in development).

Explore

eHealth - The Future of Healthcare

Our implantable eHealth platform, not yet available, is designed to dramatically change healthcare.

Step into the future


Potential paradigm shift in acid reflux treatment

This CE marked device is based on a unique invention that treats the cause of acid reflux, a treatment field affecting 19% of the US and 17% of the EU population weekly1.

Learn more about RefluxStopTM

Capital Markets Day

September 26, 2023

Watch the webcast


Press releases

Read all press releases

  1. 1. Nirwan, J.S., Hasan, S.S., Babar, ZUD. et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep 10, 5814 (2020). https://doi.org/10.1038/s41598-020-62795-1

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here